1. Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting

2. Outline Slide Presented By Leora Horn at 2014 ASCO Annual Meeting

3. Slide 3 Presented By Leora Horn at 2014 ASCO Annual Meeting

4. LUX-Lung 3 and 6: design Presented By Leora Horn at 2014 ASCO Annual Meeting

5. Combined OS analysis: common mutations (n=631) Presented By Leora Horn at 2014 ASCO Annual Meeting

6. Combined OS analysis: mutation categories Presented By Leora Horn at 2014 ASCO Annual Meeting

7. JO25567 Study Design Presented By Leora Horn at 2014 ASCO Annual Meeting

8. Primary endpoint: PFS by independent review Presented By Leora Horn at 2014 ASCO Annual Meeting

9. PFS by EGFR Mutation Type Presented By Leora Horn at 2014 ASCO Annual Meeting

10. Acquired Resistance to EGFR TKIs Presented By Leora Horn at 2014 ASCO Annual Meeting

11. Phase I Trials With Third Generation EGFR Inhibitors Presented By Leora Horn at 2014 ASCO Annual Meeting

12. Phase I Trials Presented By Leora Horn at 2014 ASCO Annual Meeting

13. AZD9291: Response rate* in T790M+ (central test) Presented By Leora Horn at 2014 ASCO Annual Meeting

14. CO-1686: Best response in Phase 1 and early Phase 2 expansion cohort patients Presented By Leora Horn at 2014 ASCO Annual Meeting

15. HM61713: Response in T790M Cohort Presented By Leora Horn at 2014 ASCO Annual Meeting

16. RADIANT Trial Design Presented By Leora Horn at 2014 ASCO Annual Meeting

17. Disease-free Survival KM Plot – FAS Presented By Leora Horn at 2014 ASCO Annual Meeting

18. Slide 18 Presented By Leora Horn at 2014 ASCO Annual Meeting

19. Slide 19 Presented By Leora Horn at 2014 ASCO Annual Meeting

20. Summary Presented By Leora Horn at 2014 ASCO Annual Meeting

21. PROFILE 1014 Study Design Presented By Leora Horn at 2014 ASCO Annual Meeting

22. Primary Endpoint Met: Crizotinib Superior to Pemetrexed-based Chemotherapy in Prolonging PFSa Presented By Leora Horn at 2014 ASCO Annual Meeting

23. ASCEND-1 Study Design Presented By Leora Horn at 2014 ASCO Annual Meeting

24. Progression-Free Survival in Patients with ALK+ NSCLC Presented By Leora Horn at 2014 ASCO Annual Meeting

25. Summary Presented By Leora Horn at 2014 ASCO Annual Meeting

26. REVEL: Study Design Presented By Leora Horn at 2014 ASCO Annual Meeting

27. Overall Survival ITT Population Presented By Leora Horn at 2014 ASCO Annual Meeting

28. Study Design: Squire Presented By Leora Horn at 2014 ASCO Annual Meeting

29. Slide 29 Presented By Leora Horn at 2014 ASCO Annual Meeting

30. Summary Presented By Leora Horn at 2014 ASCO Annual Meeting

31. CREST Trial Design Presented By Leora Horn at 2014 ASCO Annual Meeting

32. Overall survival Presented By Leora Horn at 2014 ASCO Annual Meeting

33. PCI in SCLC: Trial Design Presented By Leora Horn at 2014 ASCO Annual Meeting

34. Time to Brain Metastasis Presented By Leora Horn at 2014 ASCO Annual Meeting

35. Overall Survival Presented By Leora Horn at 2014 ASCO Annual Meeting

36. Summary Presented By Leora Horn at 2014 ASCO Annual Meeting

37. KEYNOTE-001: First line therapy with MK3475 in patients with PD-L1 positive NSCLC Presented By Leora Horn at 2014 ASCO Annual Meeting

38. Antitumor Activity by MK-3475 Dose Presented By Leora Horn at 2014 ASCO Annual Meeting

39. Conclusions Presented By Leora Horn at 2014 ASCO Annual Meeting